Quantcast
Last updated on April 18, 2014 at 21:21 EDT

The Breast Cancer Therapeutics Market in Australia

August 5, 2009

SYDNEY, Aug. 5 /PRNewswire/ — Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia’s female population, the total number of breast cancer patients in the country was 164,814 in 2008. This figure is estimated to reach 304,511 patients by 2013. Globally, breast cancer is second to lung cancer as the cause of death among women.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Initiatives such as the BreastScreen Australia program, which provides free mammography services to aid in the early detection of breast cancer, have resulted in oncologists seeing more early stage disease. This, combined with aggressive and targeted therapy has, in turn, resulted in a reduction in the number of locally-advanced and metastatic breast cancer patients in the country.

The use of molecular targeted therapies as effective forms of cancer therapy is becoming more prevalent. These therapies are specifically designed to target cancer cells, while minimizing the adverse effects on normal cells when compared to cytotoxic chemotherapeutic drugs. New offerings must constitute therapies that will improve quality of life and survival rates if they are to thrive in this highly competitive market.

“Biopharmaceutical companies are placing more emphasis on developing targeted breast cancer therapies that offer patients not only increased efficacy, but reduced side effects as well,” explains Carole Gaffud, Frost & Sullivan Research Analyst. “There are several new targeted therapies and chemotherapy drugs under development, including Epotheliones and Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors.”

However, chemotherapy continues to be used widely for now. This may be attributed to the fact that the use of targeted therapy is limited due to access and affordability issues, thereby making those complements rather than substitutes for chemotherapy. “Due to higher cost compared to cytotoxic and hormonal therapies, the use of targeted therapies in Australia is and will continue to be largely dependent on their price and availability on the Pharmaceutical Benefits Scheme (PBS),” says Gaffud.

Currently, only Herceptin (for early stage breast cancer patients) and Tykerb (for advanced/metastatic breast cancer patients) are subsidized through the PBS. Nonetheless, innovative targeted therapies are showing great promise and are being touted as the future of breast cancer treatment. Combinations of these highly specific therapies with existing cytotoxic and hormonal therapies will soon become the standard of oncology care.

Frost & Sullivan’s latest research service on The Breast Cancer Therapeutics Market in Australia provides competitive structure, market analysis and future trends for the breast cancer drug therapies (cytotoxic, hormonal and targeted) in Australia.

This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team(TM) are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jasminder Kaur
    Corporate Communications -Healthcare, Asia Pacific
    DID: +65 6890 0937
    Email: jkaur@frost.com

    Emmie Kaur
    Corporate Communications -Healthcare, Asia Pacific
    DID: +603 6204 5913
    Email: emmie.kaur@frost.com

SOURCE Frost & Sullivan


Source: newswire